AZN · NYSE
AstraZeneca PLC
$172.28 -0.38 (-0.22%)
Company overview
AstraZeneca PLC is a biopharmaceutical company focused on the discovery, development, manufacture, and commercialization of prescription medicines. Its marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology indications. Its portfolio also includes Vaxzevria, Beyfortus, Synagis, FluMist, Soliris, Ultomiris, Strensiq, Koselugo, and Kanuma for covid-19 and rare diseases. The company serves primary care and specialty care physicians through distributors and local representative offices in the United Kingdom, rest of Europe, the Americas, Asia, Africa, and Australasia.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- Exchange
- NYSE
- Market cap
- $267B
- Employees
- 94,300
- Headquarters
- Cambridge
- Website
- astrazeneca.com
- CEO
- Pascal Claude Roland Soriot
- Listed
- May 12, 1993
- P/E
- 25.68
- Dividend yield
- 2.00%
Company financials
- Revenue
- $60.4B
- Gross profit
- $49.4B
- Operating income
- $14.3B
- EBITDA
- $20.5B
- Net income
- $10.4B
- EPS
- $6.71
- Total assets
- $114B
- Total debt
- $33.9B
- Gross margin
- 81.68%
- Net margin
- 17.19%
- Earnings yield
- 3.89%
Showing FY 2025
AZN
1D
NYSE
O169.86H173.91L169.32C172.57+4.12 (+2.45%)Vol2.77M